低分子肝素在老年患者经皮冠状动脉成形术中的应用

The application of Low Molecular Heparin in PCI of older patients

目的:探讨低分子肝素在老年患者经皮冠状动脉介入治疗(PCI)中应用的安全性和有效性。方法:106例经皮冠状动脉介入治疗冠心病患者分为两组:A组为术中用体重校正低分子肝素钠(LMWH);B组为PCI术中常规用普通肝素(UFH)。结果:两组的一般临床资料比较差异无显著性。A组与B组手术成功率(97.9%和98.8%)、30d内再次血运重建(1例与3例)、急性血栓形成和周围血管并发症(0例与1例)比较差异均无显著性(P>0.05)。结论:低分子肝素在PCI术中的应用是有效的、安全的。

Obsjective：to approach the security and efficacy of the Low Molecular Heparin in percutaneous coronary intervention of older patients（PCI）. Methods： 106 patients with coronary heart disease through PCI were divided into two groups ,from Sep. 2007 to Aug. 2008. Group A used low molecular weight hepairin （LMWH）, such as enoxaparin（ trade name Clexane ） during PCI;Group B used routine unfractionated hepari （UFH） ,during PCI There were 51 patients in group A,28male and 23 female;the average ages were 70. 1 ± 4.5 years old; there were 55patients in group B,26 male and 29 female,the average ages were 64.6 ± 2.6 years old. Results： to compare the nomoral clinical datas between the two groups, the differences had no singificanee. The comparison of differences in the achievement ratio of group A and B （97.9% 与 98.8% ）, revascularization in 30 days （lpou and 3pou）, the acute thrombopoiesis and Peripheral vascular complication （Opou and lpou） were no singificance（P 〉0.05）. Conclusion：using LMWH in PCI is efficacy and security.